Table 4.  Body weight, plasma and urinary parameters, and relative values of effort test, before (D0) and after (D30) supplementation of GE or placebo in handball players. Values are means (±SEM) of 10 determinations performed in duplicate on samples from different subjects; n = 10 handball players.
 
Placebo n=10
Grape extract n=10
 
D0
D30
D0
D30

Weight (kg)

88.5 (5.7)
86.5 (5.4)
88.4 (5.7)
87.1 (5.7)

Biomarkers of antioxidant status and oxidative stress

ORAC (µmol·L-1)

13 678 (487)
13 946 (482)
13 336 (384)
15 132 (536) ***

FRAP (µmol·L-1 Fe2+)

1 168 (57)
988 (39) ***
1 110 (45)
1 060 (55) #

LDLox (mU·mL-1)

537 (174)
562 (189)
622 (202)
693 (229)

SOD (U·g-1 Hb)

2 381 (116)
2 549 (122) *
2 710 (157)
2 679 (113) #

GPx (µmol·min-1·g -1 Hb)

17.0 (1.4)
14.2 (1.5) *
18.8 (1.7)
18.0 (1.6) #

Catalase (mol·min-1.g -1 Hb)

.580 (.056)
.545 (.090)
.640 (.044)
.681 (.088)

Vitamin E (µg·mL-1)

12.0 (.5)
12.0 (.7)
12.2 (.6)
12.9 (.7) ##

Vit E/cholesterol ratio (µg·mg-1)

6.7 (.3)
6.9 (.3)
6.9 (.4)
7.5 (.5) *#

Vit C (µmol·L-1)

65.8 (9.1)
55.5 (9.1)
59.3 (5.1)
54.7 (5.8)

Isoprostanes (ng·mg-1 creatinine)

1.3 (.1)
1.7 (.2) *
1.3 (.2)
1.3 (.2) #

Biomarker of skeletal muscle damage

Creatine phosphokinase (UI·L-1)

704 (223)
725 (326)
790 (300)
464 (120)

General plasmatic biomarkers

Triglycerides (g·L-1)

.47 (.04)
.58 (.07)
.53 (.05)
.66 (.10)

Cholesterol (g·L-1)

1.81 (.1)
1.76 (.10)
1.78 (.10)
1.78 (.10)

Ferritin (µg·L-1)

69.1 (14.7)
57.8 (13.3) *
68.8 (15.5)
56.8 (13.0) *

Urea (g·L-1)

.29 (.02)
.28 (.01)
.30 (.05)
.27 (.06)

Triglycerides (g·L-1)

14.6 (.20)
14.56 (.19)
14.52 (.21)
14.87 (.30) *

Effort test

Performance (EnRJ45, %)

-4.4 (6.1)
19.5 (9.7)

Explosive power (RJ110, %)

-3.57 (2.50)
2.82 (4.25)

Fatigue (RJ5, %)

2.95 (3.47)
10.85 (6.88)
*, ** and *** denote p < 0.05 , p < 0.01 and p < 0.001, respectively, from the pre-treatment (D0) by paired t test. # and ## denote p < 0.05 and p < 0.01, respectively, from the placebo post-treatment (D30) by paired t test. † significantly (p < 0.05) different from the placebo relative values by paired z test. ‡ significantly (p < 0.05) different from the placebo pre-treatment (D0).